Tandem Diabetes Care Stock Buy Hold or Sell Recommendation

TNDM Stock  USD 19.17  0.99  5.45%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tandem Diabetes Care is 'Sell'. The recommendation algorithm takes into account all of Tandem Diabetes' available fundamental, technical, and predictive indicators you will find on this site.
  
Check out Tandem Diabetes Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
Note, we conduct extensive research on individual companies such as Tandem and provide practical buy, sell, or hold advice based on investors' constraints. Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Execute Tandem Diabetes Buy or Sell Advice

The Tandem recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tandem Diabetes Care. Macroaxis does not own or have any residual interests in Tandem Diabetes Care or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tandem Diabetes' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Tandem DiabetesBuy Tandem Diabetes
Sell

Market Performance

Very WeakDetails

Volatility

Not too volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Almost mirrors the marketDetails

Investor Sentiment

InterestedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Tandem Diabetes Care has a Mean Deviation of 2.88, Standard Deviation of 5.28 and Variance of 27.91
Our advice tool can cross-verify current analyst consensus on Tandem Diabetes and to analyze the firm potential to grow in the current economic cycle. To make sure Tandem Diabetes Care is not overpriced, please validate all Tandem Diabetes fundamentals, including its revenue, cash flow from operations, current asset, as well as the relationship between the cash per share and beta . Given that Tandem Diabetes Care has a number of shares shorted of 7.08 M, we advise you to double-check Tandem Diabetes Care market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Tandem Diabetes Trading Alerts and Improvement Suggestions

Tandem Diabetes Care generated a negative expected return over the last 90 days
Tandem Diabetes Care has high historical volatility and very poor performance
The company reported the previous year's revenue of 940.2 M. Net Loss for the year was (96.03 M) with profit before overhead, payroll, taxes, and interest of 489.57 M.
Over 99.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. - Defense World

Tandem Diabetes Returns Distribution Density

The distribution of Tandem Diabetes' historical returns is an attempt to chart the uncertainty of Tandem Diabetes' future price movements. The chart of the probability distribution of Tandem Diabetes daily returns describes the distribution of returns around its average expected value. We use Tandem Diabetes Care price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tandem Diabetes returns is essential to provide solid investment advice for Tandem Diabetes.
Mean Return
-0.52
Value At Risk
-6.14
Potential Upside
5.35
Standard Deviation
5.28
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tandem Diabetes historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Tandem Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as Tandem Diabetes, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Tandem Diabetes Care back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
Shares
Champlain Investment Partners, Llc2024-12-31
1.4 M
Hood River Capital Management Llc2024-12-31
1.3 M
Fmr Inc2024-12-31
1.1 M
Chicago Capital, Llc2024-12-31
970.6 K
Marshall Wace Asset Management Ltd2024-12-31
950.9 K
Gilder Gagnon Howe & Co Llc2024-12-31
931.9 K
Brown Advisory Holdings Inc2024-12-31
913.1 K
Paradice Investment Management Llc2024-09-30
903.4 K
Two Sigma Advisers, Llc2024-12-31
881.8 K
Blackrock Inc2024-12-31
11.7 M
Vanguard Group Inc2024-12-31
7.4 M
Note, although Tandem Diabetes' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tandem Diabetes Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash43.4M(23.4M)101.3M(113.6M)10.4M10.9M
Free Cash Flow(7.6M)87.8M7.5M(83.4M)5.0M5.2M
Depreciation10.5M13.8M14.3M15.7M14.3M8.5M
Other Non Cash Items28.9M2.3M50.5M104.7M4.6M4.4M
Capital Expenditures32.3M23.5M43.0M51.6M19.2M18.1M
Net Income(34.4M)15.6M(94.6M)(222.6M)(96.0M)(100.8M)
End Period Cash Flow94.6M71.2M172.5M58.9M69.2M66.2M
Change To Inventory(15.4M)(5.0M)(42.5M)(46.1M)5.8M6.1M
Investments(263.8M)(163.4M)33.2M(85.7M)(23.5M)(24.7M)
Change Receivables(13.7M)(38.8M)(31.0M)(7.8M)(7.0M)(7.4M)
Change To Netincome73.5M76.4M65.5M121.7M140.0M147.0M

Tandem Diabetes Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tandem Diabetes or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tandem Diabetes' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tandem stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.42
β
Beta against Dow Jones0.99
σ
Overall volatility
5.31
Ir
Information ratio -0.08

Tandem Diabetes Volatility Alert

Tandem Diabetes Care exhibits very low volatility with skewness of -4.38 and kurtosis of 28.78. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tandem Diabetes' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tandem Diabetes' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Tandem Diabetes Fundamentals Vs Peers

Comparing Tandem Diabetes' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tandem Diabetes' direct or indirect competition across all of the common fundamentals between Tandem Diabetes and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tandem Diabetes or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tandem Diabetes' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Tandem Diabetes to competition
FundamentalsTandem DiabetesPeer Average
Return On Equity-0.33-0.31
Return On Asset-0.0645-0.14
Profit Margin(0.10) %(1.27) %
Operating Margin(0) %(5.51) %
Current Valuation1.31 B16.62 B
Shares Outstanding66.47 M571.82 M
Shares Owned By Insiders0.84 %10.09 %
Shares Owned By Institutions99.16 %39.21 %
Number Of Shares Shorted7.08 M4.71 M
Price To Earning494.25 X28.72 X
Price To Book4.85 X9.51 X
Price To Sales1.36 X11.42 X
Revenue940.2 M9.43 B
Gross Profit489.57 M27.38 B
EBITDA(99.13 M)3.9 B
Net Income(96.03 M)570.98 M
Cash And Equivalents608.73 M2.7 B
Cash Per Share9.47 X5.01 X
Total Debt473.56 M5.32 B
Debt To Equity1.00 %48.70 %
Current Ratio4.80 X2.16 X
Book Value Per Share3.97 X1.93 K
Cash Flow From Operations24.23 M971.22 M
Short Ratio4.39 X4.00 X
Earnings Per Share(1.47) X3.12 X
Target Price41.65
Number Of Employees2.65 K18.84 K
Beta1.45-0.15
Market Capitalization1.27 B19.03 B
Total Asset967.66 M29.47 B
Retained Earnings(1.05 B)9.33 B
Working Capital477.44 M1.48 B
Current Asset106.98 M9.34 B
Note: Acquisition by Shannon Hansen of 531 shares of Tandem Diabetes subject to Rule 16b-3 [view details]

Tandem Diabetes Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tandem . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Tandem Diabetes Buy or Sell Advice

When is the right time to buy or sell Tandem Diabetes Care? Buying financial instruments such as Tandem Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Tandem Diabetes in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Market Funds Thematic Idea Now

Money Market Funds
Money Market Funds Theme
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out Tandem Diabetes Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(1.47)
Revenue Per Share
14.365
Quarterly Revenue Growth
0.436
Return On Assets
(0.06)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.